- Home
- UAMY vs GNFT Comparison
UAMY vs GNFT Comparison
Compare UAMY & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- GNFT
- Stock Information
- Founded
- UAMY 1968
- GNFT 1999
- Country
- UAMY United States
- GNFT France
- Employees
- UAMY N/A
- GNFT N/A
- Industry
- UAMY Metal Fabrications
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UAMY Industrials
- GNFT Health Care
- Exchange
- UAMY Nasdaq
- GNFT Nasdaq
- Market Cap
- UAMY 251.9M
- GNFT 214.5M
- IPO Year
- UAMY N/A
- GNFT 2019
- Fundamental
- Price
- UAMY $2.22
- GNFT N/A
- Analyst Decision
- UAMY Strong Buy
- GNFT Strong Buy
- Analyst Count
- UAMY 4
- GNFT 1
- Target Price
- UAMY $3.38
- GNFT $13.00
- AVG Volume (30 Days)
- UAMY 5.3M
- GNFT 4.2K
- Earning Date
- UAMY 08-08-2025
- GNFT 04-24-2025
- Dividend Yield
- UAMY N/A
- GNFT N/A
- EPS Growth
- UAMY N/A
- GNFT N/A
- EPS
- UAMY N/A
- GNFT 0.03
- Revenue
- UAMY $18,865,900.00
- GNFT $73,187,701.00
- Revenue This Year
- UAMY $270.45
- GNFT $15.98
- Revenue Next Year
- UAMY $104.06
- GNFT N/A
- P/E Ratio
- UAMY N/A
- GNFT $125.30
- Revenue Growth
- UAMY 97.46
- GNFT 105.01
- 52 Week Low
- UAMY $0.27
- GNFT $2.55
- 52 Week High
- UAMY $3.86
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- UAMY 39.44
- GNFT 46.56
- Support Level
- UAMY $2.71
- GNFT $3.61
- Resistance Level
- UAMY $2.71
- GNFT $3.95
- Average True Range (ATR)
- UAMY 0.24
- GNFT 0.14
- MACD
- UAMY -0.07
- GNFT -0.01
- Stochastic Oscillator
- UAMY 24.14
- GNFT 50.64
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has four operating segments: United States Antimony, Mexican antimony, zeolite, and Precious metals. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.